<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223378</url>
  </required_header>
  <id_info>
    <org_study_id>659</org_study_id>
    <nct_id>NCT01223378</nct_id>
  </id_info>
  <brief_title>Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension</brief_title>
  <acronym>Voyager</acronym>
  <official_title>A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to determine the most effective drug
      concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical
      development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2010</start_date>
  <completion_date type="Actual">June 22, 2012</completion_date>
  <primary_completion_date type="Actual">December 20, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Diurnal IOP at Visit 6 (Day 28)</measure>
    <time_frame>Baseline and Visit 6 (Day 28)</time_frame>
    <description>Determine the most effective drug concentration(s) of BOL-303259-X in the reduction of intraocular pressure (IOP) and compared to latanoprost</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Diurnal IOP at Visits 4,5, and 7</measure>
    <time_frame>Baseline and Visit 4 (Day 7), Visit 5 (day 14), and Visit 7 (Day 29)</time_frame>
    <description>Determine the most effective drug concentration(s) of BOL-303259-X in the reduction of intraocular pressure (IOP) and compared to latanoprost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP &lt;/=18mm Hg</measure>
    <time_frame>Visit 4 (Day 7), Visit 5 (day 14), Visit 6 (Day 28) and Visit 7 (Day 29)</time_frame>
    <description>Determine the number of subjects with mean diurnal IOP &lt;/=18 mm Hg with BOL-303259-X versus latanoprost ophthalmic solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visit 6 (Day 28)</measure>
    <time_frame>baseline and Visit 6 (Day 28)</time_frame>
    <description>The change in the observed mean study eye IOP from baseline (Visit 3, Day 1) at specified time points (8 AM, 12 PM, 4 PM) at Visit 6 (Day 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visits 4, 5, and 7 (Days 7, 14, and 29)</measure>
    <time_frame>baseline and Visits 4, 5 and 7 (Days 7, 14, and 29)</time_frame>
    <description>The change in the observed mean study eye IOP from baseline (Visit 3, Day 1) at specified time points (points 8 AM, 12 PM, and 4 PM) at Visits 4, 5, and 7 (Days 7, 14, and 29)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">413</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>BOL-303259-X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-303259-X</intervention_name>
    <description>ophthalmic solution, various concentrations, once daily (QD) 28 days</description>
    <arm_group_label>BOL-303259-X</arm_group_label>
    <other_name>latanoprostene bunod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>0.005% ophthalmic solution, QD 28 days</description>
    <arm_group_label>Latanoprost</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a diagnosis of open angle glaucoma (OAG) or ocular hypertension
             (OH) in one or both eyes.

          -  IOP requirements at Visit 3, A mean/median IOP ≥ 26 mmHg at a minimum of 1 time point,
             ≥ 24 mmHg at a minimum of 1 time point, and ≥ 22 mmHg at 1 time point in the same eye,
             and Mean/median IOP ≤ 32 mmHg in both eyes at all 3 measurement time points.

          -  Subjects with best-corrected visual acuity (BCVA), using Early Treatment of Diabetic
             Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent ~20/100)
             or better in either eye.

        Exclusion Criteria:

          -  Subjects with a known hypersensitivity or contraindications to latanoprost or any of
             the ingredients in the study drugs.

          -  Subjects with known contraindications to nitric oxide (NO) treatment.

          -  Subjects whose central corneal thickness was greater than 600um in either eye.

          -  Subjects with any condition that prevented reliable applanation tonometry in either
             eye.

          -  Subjects with advanced glaucoma and subjects with a cup/disc ratio greater than 0.8 or
             a history of split fixation, or a field loss threatening fixation in either eye.

          -  Subjects with previous or active corneal disease.

          -  Subjects with a history of severe dry eye.

          -  Subjects with monophthalmia.

          -  Subjects with optic disc hemorrhage.

          -  Subjects with a history of central retinal vein and artery occlusion.

          -  Subjects with a history of macular edema.

          -  Subjects with any intraocular infection, inflammation, or laser surgery within the
             previous 6 months from Visit 1 (Screening).

          -  Subjects who had incisional ocular surgery or severe trauma within the previous 6
             months from Visit 1 (Screening).

          -  Subjects with very narrow angles (3 quadrants with less than Grade 2 according to
             Shaffer's anterior chamber angle grading system) and subjects with angle closure,
             congenital and secondary glaucoma, and subjects with history of angle closure in
             either eye.

          -  Subjects with a diagnosis of a clinically significant or progressive retinal disease
             in either eye.

          -  Subjects who were expected to require treatment with ocular or systemic
             corticosteroids.

          -  Subjects who were in need of any other topical or systemic treatment of OAG or OHT.

          -  Subjects with an anticipated need to initiate or modify medication (systemic or
             topical) that was known to affect IOP during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rabia Ozden, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb, Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER study group. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015 Jun;99(6):738-45. doi: 10.1136/bjophthalmol-2014-305908. Epub 2014 Dec 8.</citation>
    <PMID>25488946</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <results_first_submitted>May 18, 2018</results_first_submitted>
  <results_first_submitted_qc>June 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2018</results_first_posted>
  <disposition_first_submitted>August 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 20, 2012</disposition_first_posted>
  <last_update_submitted>June 27, 2018</last_update_submitted>
  <last_update_submitted_qc>June 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled on 13 Dec 2010, Last subject exited on 20 Dec 2011. This study was conducted at 23 clinical sites. US [15 sites], Bulgaria [3 sites], Poland [3 sites], and Czech Republic [2 sites]).</recruitment_details>
      <pre_assignment_details>Subjects who were currently under treatment with an IOP-lowering medication at Visit 1 were required to discontinue the IOP medication during the washout period (minimum of 28 days) between Visit 1 and Visit 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BOL-303259-X 0.006%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.006%, once daily (QD) 28 days</description>
        </group>
        <group group_id="P2">
          <title>BOL-303259-X 0.012%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.012%, once daily (QD) 28 days</description>
        </group>
        <group group_id="P3">
          <title>BOL-303259-X 0.024%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.024%, once daily (QD) 28 days</description>
        </group>
        <group group_id="P4">
          <title>BOL-303259-X 0.040%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.040%, once daily (QD) 28 days</description>
        </group>
        <group group_id="P5">
          <title>Latanoprost</title>
          <description>ophthalmic solution
Latanoprost: 0.005% ophthalmic solution, QD 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>BOL-303259-X 0.006%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.006%, once daily (QD) 28 days</description>
        </group>
        <group group_id="B2">
          <title>BOL-303259-X 0.012%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.012%, once daily (QD) 28 days</description>
        </group>
        <group group_id="B3">
          <title>BOL-303259-X 0.024%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.024%, once daily (QD) 28 days</description>
        </group>
        <group group_id="B4">
          <title>BOL-303259-X 0.040%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.040%, once daily (QD) 28 days</description>
        </group>
        <group group_id="B5">
          <title>Latanoprost</title>
          <description>ophthalmic solution
Latanoprost: 0.005% ophthalmic solution, QD 28 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="81"/>
            <count group_id="B5" value="82"/>
            <count group_id="B6" value="413"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="11.39"/>
                    <measurement group_id="B2" value="61.6" spread="9.58"/>
                    <measurement group_id="B3" value="60.8" spread="11.47"/>
                    <measurement group_id="B4" value="60.3" spread="12.89"/>
                    <measurement group_id="B5" value="61.2" spread="11.92"/>
                    <measurement group_id="B6" value="61.0" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="381"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="306"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Diurnal IOP at Visit 6 (Day 28)</title>
        <description>Determine the most effective drug concentration(s) of BOL-303259-X in the reduction of intraocular pressure (IOP) and compared to latanoprost</description>
        <time_frame>Baseline and Visit 6 (Day 28)</time_frame>
        <population>Intent-to-treat population, observed data (study eye)</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X 0.006%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.006%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O2">
            <title>BOL-303259-X 0.012%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.012%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O3">
            <title>BOL-303259-X 0.024%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.024%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O4">
            <title>BOL-303259-X 0.040%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.040%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost</title>
            <description>ophthalmic solution
Latanoprost: 0.005% ophthalmic solution, QD 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Diurnal IOP at Visit 6 (Day 28)</title>
          <description>Determine the most effective drug concentration(s) of BOL-303259-X in the reduction of intraocular pressure (IOP) and compared to latanoprost</description>
          <population>Intent-to-treat population, observed data (study eye)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.829" spread="2.823"/>
                    <measurement group_id="O2" value="-8.295" spread="2.864"/>
                    <measurement group_id="O3" value="-8.952" spread="3.337"/>
                    <measurement group_id="O4" value="-8.894" spread="2.666"/>
                    <measurement group_id="O5" value="-7.800" spread="2.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Diurnal IOP at Visits 4,5, and 7</title>
        <description>Determine the most effective drug concentration(s) of BOL-303259-X in the reduction of intraocular pressure (IOP) and compared to latanoprost</description>
        <time_frame>Baseline and Visit 4 (Day 7), Visit 5 (day 14), and Visit 7 (Day 29)</time_frame>
        <population>Intent-to-treat population, observed data (study eye)</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X 0.006%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.006%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O2">
            <title>BOL-303259-X 0.012%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.012%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O3">
            <title>BOL-303259-X 0.024%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.024%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O4">
            <title>BOL-303259-X 0.040%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.040%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost</title>
            <description>ophthalmic solution
Latanoprost: 0.005% ophthalmic solution, QD 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Diurnal IOP at Visits 4,5, and 7</title>
          <description>Determine the most effective drug concentration(s) of BOL-303259-X in the reduction of intraocular pressure (IOP) and compared to latanoprost</description>
          <population>Intent-to-treat population, observed data (study eye)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.850" spread="2.768"/>
                    <measurement group_id="O2" value="-7.707" spread="3.192"/>
                    <measurement group_id="O3" value="-8.230" spread="3.286"/>
                    <measurement group_id="O4" value="-8.456" spread="2.892"/>
                    <measurement group_id="O5" value="-7.325" spread="2.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Day 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.607" spread="2.204"/>
                    <measurement group_id="O2" value="-7.934" spread="3.065"/>
                    <measurement group_id="O3" value="-8.859" spread="3.300"/>
                    <measurement group_id="O4" value="-8.606" spread="2.878"/>
                    <measurement group_id="O5" value="-7.719" spread="3.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Day 29)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.188" spread="2.782"/>
                    <measurement group_id="O2" value="-6.202" spread="3.001"/>
                    <measurement group_id="O3" value="-7.177" spread="3.615"/>
                    <measurement group_id="O4" value="-6.846" spread="3.135"/>
                    <measurement group_id="O5" value="-6.276" spread="2.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IOP &lt;/=18mm Hg</title>
        <description>Determine the number of subjects with mean diurnal IOP &lt;/=18 mm Hg with BOL-303259-X versus latanoprost ophthalmic solution</description>
        <time_frame>Visit 4 (Day 7), Visit 5 (day 14), Visit 6 (Day 28) and Visit 7 (Day 29)</time_frame>
        <population>Intent-to-treat population, observed data (study eye)</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X 0.006%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.006%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O2">
            <title>BOL-303259-X 0.012%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.012%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O3">
            <title>BOL-303259-X 0.024%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.024%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O4">
            <title>BOL-303259-X 0.040%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.040%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost</title>
            <description>ophthalmic solution
Latanoprost: 0.005% ophthalmic solution, QD 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>IOP &lt;/=18mm Hg</title>
          <description>Determine the number of subjects with mean diurnal IOP &lt;/=18 mm Hg with BOL-303259-X versus latanoprost ophthalmic solution</description>
          <population>Intent-to-treat population, observed data (study eye)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Day 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 28)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Day 29)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visit 6 (Day 28)</title>
        <description>The change in the observed mean study eye IOP from baseline (Visit 3, Day 1) at specified time points (8 AM, 12 PM, 4 PM) at Visit 6 (Day 28)</description>
        <time_frame>baseline and Visit 6 (Day 28)</time_frame>
        <population>Intent to treat, data as observed (study eye)</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X 0.006%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.006%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O2">
            <title>BOL-303259-X 0.012%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.012%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O3">
            <title>BOL-303259-X 0.024%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.024%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O4">
            <title>BOL-303259-X 0.040%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.040%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost</title>
            <description>ophthalmic solution
Latanoprost: 0.005% ophthalmic solution, QD 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visit 6 (Day 28)</title>
          <description>The change in the observed mean study eye IOP from baseline (Visit 3, Day 1) at specified time points (8 AM, 12 PM, 4 PM) at Visit 6 (Day 28)</description>
          <population>Intent to treat, data as observed (study eye)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline (8 am)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.42" spread="3.69"/>
                    <measurement group_id="O2" value="-8.91" spread="3.24"/>
                    <measurement group_id="O3" value="-9.46" spread="4.01"/>
                    <measurement group_id="O4" value="-9.61" spread="2.95"/>
                    <measurement group_id="O5" value="-8.76" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (12 pm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.82" spread="3.34"/>
                    <measurement group_id="O2" value="-8.33" spread="3.35"/>
                    <measurement group_id="O3" value="-8.98" spread="3.50"/>
                    <measurement group_id="O4" value="-8.60" spread="3.23"/>
                    <measurement group_id="O5" value="-7.63" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (4 pm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.23" spread="2.97"/>
                    <measurement group_id="O2" value="-7.65" spread="3.37"/>
                    <measurement group_id="O3" value="-8.59" spread="3.54"/>
                    <measurement group_id="O4" value="-8.47" spread="3.28"/>
                    <measurement group_id="O5" value="-6.99" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visits 4, 5, and 7 (Days 7, 14, and 29)</title>
        <description>The change in the observed mean study eye IOP from baseline (Visit 3, Day 1) at specified time points (points 8 AM, 12 PM, and 4 PM) at Visits 4, 5, and 7 (Days 7, 14, and 29)</description>
        <time_frame>baseline and Visits 4, 5 and 7 (Days 7, 14, and 29)</time_frame>
        <population>Intent-to-treat, observed data (study eye)</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X 0.006%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.006%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O2">
            <title>BOL-303259-X 0.012%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.012%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O3">
            <title>BOL-303259-X 0.024%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.024%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O4">
            <title>BOL-303259-X 0.040%</title>
            <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.040%, once daily (QD) 28 days</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost</title>
            <description>ophthalmic solution
Latanoprost: 0.005% ophthalmic solution, QD 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visits 4, 5, and 7 (Days 7, 14, and 29)</title>
          <description>The change in the observed mean study eye IOP from baseline (Visit 3, Day 1) at specified time points (points 8 AM, 12 PM, and 4 PM) at Visits 4, 5, and 7 (Days 7, 14, and 29)</description>
          <population>Intent-to-treat, observed data (study eye)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (Day 7) (8 am)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.203" spread="3.634"/>
                    <measurement group_id="O2" value="-8.396" spread="3.935"/>
                    <measurement group_id="O3" value="-8.667" spread="3.827"/>
                    <measurement group_id="O4" value="-8.869" spread="3.384"/>
                    <measurement group_id="O5" value="-8.125" spread="2.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 7) (12 pm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.665" spread="3.046"/>
                    <measurement group_id="O2" value="-7.823" spread="3.409"/>
                    <measurement group_id="O3" value="-8.247" spread="3.643"/>
                    <measurement group_id="O4" value="-8.219" spread="3.338"/>
                    <measurement group_id="O5" value="-7.200" spread="3.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 7) (4 pm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.684" spread="3.246"/>
                    <measurement group_id="O2" value="-6.902" spread="3.371"/>
                    <measurement group_id="O3" value="-7.778" spread="3.479"/>
                    <measurement group_id="O4" value="-8.281" spread="3.172"/>
                    <measurement group_id="O5" value="-6.650" spread="3.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Day 14) (8 am)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.270" spread="3.399"/>
                    <measurement group_id="O2" value="-8.538" spread="3.518"/>
                    <measurement group_id="O3" value="-9.569" spread="3.597"/>
                    <measurement group_id="O4" value="-9.006" spread="3.031"/>
                    <measurement group_id="O5" value="-8.519" spread="3.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Day 14) (12 pm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.500" spread="2.653"/>
                    <measurement group_id="O2" value="-8.381" spread="3.518"/>
                    <measurement group_id="O3" value="-8.700" spread="3.579"/>
                    <measurement group_id="O4" value="-8.556" spread="3.529"/>
                    <measurement group_id="O5" value="-7.519" spread="3.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Day 14) (4 pm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.053" spread="2.519"/>
                    <measurement group_id="O2" value="-6.905" spread="3.354"/>
                    <measurement group_id="O3" value="-8.310" spread="3.667"/>
                    <measurement group_id="O4" value="-8.256" spread="3.410"/>
                    <measurement group_id="O5" value="-7.120" spread="3.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Day 29) (8 am)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.969" spread="3.245"/>
                    <measurement group_id="O2" value="-6.796" spread="3.379"/>
                    <measurement group_id="O3" value="-7.675" spread="4.198"/>
                    <measurement group_id="O4" value="-7.406" spread="3.26"/>
                    <measurement group_id="O5" value="-7.006" spread="3.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Day 29) (12 pm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="79"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.039" spread="3.591"/>
                    <measurement group_id="O2" value="-6.235" spread="3.626"/>
                    <measurement group_id="O3" value="-7.119" spread="3.791"/>
                    <measurement group_id="O4" value="-6.791" spread="3.246"/>
                    <measurement group_id="O5" value="-6.108" spread="3.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Day 29) (4 pm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.575" spread="3.464"/>
                    <measurement group_id="O2" value="-5.574" spread="3.615"/>
                    <measurement group_id="O3" value="-6.738" spread="3.769"/>
                    <measurement group_id="O4" value="-6.090" spread="4.142"/>
                    <measurement group_id="O5" value="-5.715" spread="3.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The period of observation for collection of AEs extended from the time the subject gave informed consent until the last study visit (Visit 7).</time_frame>
      <desc>The safety population included one less subject in the BOL-303259-X 0.012% group than the ITT population. Hence the safety population included 412 subjects in total whereas the ITT population included 413 in total.</desc>
      <group_list>
        <group group_id="E1">
          <title>BOL-303259-X 0.006%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.006%, once daily (QD) 28 days</description>
        </group>
        <group group_id="E2">
          <title>BOL-303259-X 0.012%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.012%, once daily (QD) 28 days</description>
        </group>
        <group group_id="E3">
          <title>BOL-303259-X 0.024%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.024%, once daily (QD) 28 days</description>
        </group>
        <group group_id="E4">
          <title>BOL-303259-X 0.040%</title>
          <description>ophthalmic solution
Experimental: BOL-303259-X: ophthalmic solution, 0.040%, once daily (QD) 28 days</description>
        </group>
        <group group_id="E5">
          <title>Latanoprost</title>
          <description>ophthalmic solution
Latanoprost: 0.005% ophthalmic solution, QD 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>Acute myocardial infarction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Ulcer Hemorrhage</sub_title>
                <description>Bleeding gastric ulcer</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Hemorrage</sub_title>
                <description>Gastrointestinal bleed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <description>Gastric Ulcer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Hyperemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Conjunctival Hyperemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Abnormal Sensation in the Eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Conjunctival Follicles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Eye Lid Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Growth of Eyelashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vitreous Floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Instillation Site Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Instillation Site Lacrimation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Instillation Site Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Instillation Site Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Instillation Site Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Instillation Site Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation Site Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="84"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="81"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine with Aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H DeCory, PhD</name_or_title>
      <organization>Bausch &amp; Lomb</organization>
      <phone>585-338-8161</phone>
      <email>heleen.decory@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

